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Abstract: Carbamazepine (CBZ) has long been a therapeutic option for bipolar disorder. 
Carbamazepine extended-release capsules (CBZ-ERC) are a recent formulation of CBZ 
approved by the US Food and Drug Administration in 2004 for the treatment of acute manic 
and mixed episodes associated with bipolar I disorder. This new formulation was developed 
to improve dosing convenience and decrease daily ﬂ  uctuations in serum CBZ concentration, 
thereby lowering the incidence of adverse events. Two randomized, double-blind, 
placebo-controlled trials and an open-label extension study have demonstrated that CBZ-ERC 
monotherapy is efﬁ  cacious in patients with bipolar I disorder experiencing either manic or 
mixed episodes. In these trials, CBZ-ERC was shown to be a safe and well-tolerated therapy. 
Retrospective chart reviews conducted in private practice settings have shown that clinical 
response to CBZ-ERC is independent of bipolar subtype, as patients with bipolar I depression 
and bipolar II disorder responded similarly to patients with bipolar I disorder either manic or 
mixed episodes. CBZ is currently considered a treatment alternative to lithium and valproate 
according to the American Psychiatric Association’s treatment guidelines for patients with 
bipolar disorder. Although further study is required, the clinical evidence presented in these 
studies may change the treatment paradigm.
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Introduction
Bipolar disorder is usually a chronic illness with an episodic and variable course 
(APA 2002). It is a leading cause of years lived with disability (WHO 2004) and 
is associated with poor health-related quality of life, high utilization of health care 
services, work impairment (Dean et al 2004), and signiﬁ  cant costs to society (Wyatt 
et al 1995).
There are many forms of bipolar disorder, ranging from mild depression 
and brief hypomania to one of severe depression or mania with psychotic fea-
tures (Muller-Oerlinghausen et al 2002). To help identify the various forms of 
the illness, 4 subtypes of bipolar disorder have been deﬁ  ned based on patients’ 
clinical characteristics: bipolar I disorder, bipolar II disorder, cyclothymia, 
and bipolar disorder not otherwise speciﬁ  ed (APA 2000). Past estimates of the 
prevalence of the full spectrum of bipolar disorders have ranged from 3% to 
6.5%, with about 1% considered to be the bipolar I subtype (Angst 1998; Stimmel 
2004). Furthermore, new data on the prevalence of bipolar spectrum disorders 
have emerged from the recently completed US National Comorbidity Survey 
Replication, in which trained professionals interviewed a nationally representative 
population of 9282 English-speaking US residents aged  18 years. National 
Comorbidity Survey probands were assessed for the presence of Diagnostic 
and Statistical Manual of Mental Disorders (4th edition) mental disorders in the 
12 months prior to the survey using the World Mental Health Survey Initiative Neuropsychiatric Disease and Treatment 2006:2(1) 4
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version of the World Health Organization Composite 
International Diagnostic Interview, and it was found 
that the 12-month prevalence of bipolar disorder 
(subtype I or II) in the study sample was 2.6% (Kessler 
2005).
Treatment options
Although psychotherapy is a critical component of inter-
vention in bipolar disorder, pharmacotherapy is essential in 
treating patients who are acutely symptomatic (Suppes et al 
2005). The most recent version of the Texas Implementa-
tion of Medical Algorithms (TIMA) calls for the treatment 
of acute manic, depressive, or mixed bipolar symptoms 
to enable patients to return to normal psychosocial func-
tioning. According to the TIMA recommendations, acute 
pharmacotherapy should be initiated for mild to severe 
bipolar symptoms, with decisions on whether to maintain 
stable treatment dosing, adjust treatment dosing, or select 
an alternative pharmacotherapeutic strategy being made on 
the basis of regular follow-up assessments. Upon symptom 
remission after treatment of acute bipolar mania, a 4- to 
6-month course of continuation therapy and subsequent 
lifetime maintenance therapy with mood stabilizers are 
recommended for the prevention of recurrences (Suppes 
et al 2005).
Despite systematic guidelines for the treatment of 
bipolar disorder, the selection of appropriate therapeutic 
agents for use in conjunction with these guidelines can be 
challenging, because the symptoms of bipolar disorder 
may be very different in different phases of the illness. 
Several agents are currently available for the treatment 
of bipolar disorder, and the initial treatment depends 
on the type of episode the patient is experiencing at 
presentation. Lithium has been extensively studied in 
the treatment of acute mania and as maintenance therapy 
since the discovery of its mood-stabilizing properties 
more than 50 years ago (Goodwin et al 1969; Belmaker 
2004), and it is currently considered to be a ﬁ  rst-line 
treatment option in acute mania and prophylaxis in 
bipolar disorder. Nonetheless, despite its ﬁ  rst-line status 
and its demonstrated overall efﬁ  cacy in these settings, 
lithium therapy has been shown to be ineffective or poorly 
tolerated in a signiﬁ  cant proportion of patients (Bowden 
et al 1994). In addition, it has a narrow therapeutic range 
and requires regular blood level monitoring, as severe 
or toxic effects can occur at twice the therapeutic dose. 
Its narrow therapeutic range is an especially important 
consideration in older patients as their renal excretion 
becomes less efﬁ  cient, resulting in an increased risk of 
lithium-associated toxic effects (Goodwin 2003; Belmaker 
2004).
Although lithium is widely used globally, the anticon-
vulsants valproate and carbamazepine (CBZ) have also 
become established therapeutic options in the treatment 
of bipolar disorder (Mitchell et al 2002; Suppes et al 
2005). Extensive clinical research has shown that these 
agents have mood-stabilizing properties and are there-
fore effective treatments in the management of bipolar 
disorder (Mitchell et al 2002). The current review will 
examine data for a twice-daily extended-release capsule 
formulation of CBZ (CBZ-ERC) (Shire Pharmaceuticals, 
Wayne, PA, USA) that contains three different types of 
beads (immediate release, extended release, and enteric 
release). This particular formulation has been approved 
by the US Food and Drug Administration (FDA) for the 
treatment of acute manic and mixed episodes associated 
with bipolar I disorder.
Rationale for development of 
CBZ-ERC
Clinical evidence of the efﬁ  cacy of CBZ in the treatment 
of bipolar disorder emerged in the early 1970s. At this 
time, several small studies reported the antimanic effects 
of CBZ as well as its prophylactic effects against the 
recurrence of manic and depressive episodes in patients 
with bipolar disorder (Okuma et al 1973). Over the next 
several decades, many double-blind, controlled trials 
demonstrated the efﬁ  cacy of CBZ in the treatment of acute 
mania in bipolar disorder, with response rates similar to 
those of lithium (McElroy et al 2000). Until recently, all 
controlled evaluations of CBZ in bipolar disorder have 
used immediate-release formulations of CBZ that require 
dosing 3 or 4 times daily to avoid potentially problematic 
serum drug ﬂ  uctuations. Studies have shown that the large 
ﬂ  uctuations in serum CBZ levels observed with immediate-
release CBZ formulations are associated with intermittent 
adverse effects such as diplopia, drowsiness, and headache 
in patients with epilepsy (Hoppener et al 1980; Riva et al 
1984). The established correlation between ﬂ  uctuations 
in serum CBZ levels and intermittent side effects helped 
prompt the development of extended-release formula-
tions of CBZ for use in epilepsy. The subsequent use of 
extended-release CBZ in patients with epilepsy provided 
clinical evidence that, compared with immediate-release 
formulations, extended-release CBZ was associated with 
lower peak serum CBZ concentrations, decreased circadian Neuropsychiatric Disease and Treatment 2006:2(1) 5
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toxicity, and decreased central nervous system (CNS) side 
effects (Canger et al 1990; Haefeli et al 1994).
Non-adherence to medication is common among 
patients with bipolar disorder (Keck et al 1996; Svarstad 
et al 2001). Potential factors affecting compliance with 
medication include adverse effects and the demands of 
treatment, including frequent dosing regimens (Jamison 
et al 1983; Greenberg 1984). Since extended-release for-
mulations of CBZ have been developed to decrease daily 
ﬂ  uctuations in serum CBZ concentrations and improve dos-
ing convenience, several large clinical trials have recently 
been conducted to assess the efﬁ  cacy and tolerability of 
a novel, beaded, extended-release capsule formulation of 
CBZ in bipolar disorder (Weisler et al 2004c, 2005; Ketter 
et al 2004).
Pharmacology
Pharmacodynamics
Although recent neurochemical and neuroimaging stud-
ies have been promising, a specific pathophysiological 
abnormality in bipolar disorder has not been discovered 
(Belmaker 2004). Clinical and preclinical evidence suggests 
that second messenger systems and molecular “switches” 
known as G-proteins are involved in the underlying mecha-
nisms that result in bipolar disorder (Gould et al 2002). 
A variety of medications used to treat bipolar disorder have 
widely varying mechanisms of action (MOA), which in 
many cases are also still not well understood. Alterations 
in postreceptor pathways, intracellular signaling, neural 
plasticity, and changes in gene expression are believed to 
play important roles in the therapeutic effects of these agents 
(Gould et al 2002).
The MOA of CBZ in the treatment of bipolar disorder 
has not been clariﬁ  ed. It has been well established that 
CBZ exerts its antiepileptic effects by inhibiting the 
high-frequency ﬁ  ring of sodium channels. This effect 
produces a functional blockage of voltage-gated sodium 
channels that could be associated with its mood-stabilizing 
properties (Gould et al 2004). In experimental studies, 
CBZ acts as an antagonist at adenosine receptors, which 
are generally G-protein-coupled receptors that modu-
late neurotransmitter release and numerous behavioral 
and cognitive functions. Carbamazepine has also been 
reported to inhibit the enzyme adenylyl cyclase, which 
attenuates cyclic AMP-mediated signaling and may lead 
to inhibition of downstream activities with ion channels 
and transcription factors (Gould et al 2004). Additional 
ﬁ  ndings on the MOA of CBZ include reports of its effects 
on the voltage-gated ion channels in neurons where at 
therapeutic concentrations it acts as a calcium ion channel 
blocker (Ulrich et al 2003), and it exerts regulatory effects 
on receptor-mediated excitatory and inhibitory neurotrans-
mission (Li et al 2002).
Pharmacokinetics
The extended-release formulation CBZ-ERC utilizes a drug 
delivery system consisting of a ﬁ  xed ratio of specialized 
beads to extend the release of CBZ beyond what can be 
achieved with conventional immediate-release formulations. 
Twenty-ﬁ  ve percent of these beads are designed to release 
drug immediately after swallowing for rapid absorption, 
40% of the beads are polymer-coated to dissolve gradually 
over 8–12 hours to achieve steady-state serum CBZ levels, 
and the remaining 35% are enteric-release beads with a 
pH-sensitive coating that releases CBZ slowly in the gut to 
maintain optimal blood levels. The timed release of CBZ is 
unaffected by variations in gastrointestinal (GI) transit time. 
Additionally, the capsule does not have to be taken with food; 
it can be opened and its contents sprinkled onto soft foods 
(McLean et al 2001).
The pharmacokinetics of CBZ-ERC have been deter-
mined following single and repeat dose administration. 
Following a single 200-mg dose of CBZ-ERC, peak plasma 
CBZ concentration was found to be 1.9 ± 0.3 μg/mL, and 
time to reach peak was 19 ± 7 hours. After repeated dose 
administration of CBZ-ERC 800 mg every 12 hours, the peak 
plasma CBZ concentration was 11.0 ± 2.5 μg/mL and time 
to reach peak was 5.9 ± 1.8 hours. The pharmacokinetics of 
CBZ-ERC are linear over a single-dose range of 200–800 mg 
(Shire 2005).
CBZ is 76% bound to plasma proteins and is primarily 
metabolized in the liver. Cytochrome P450 3A4 was identi-
ﬁ  ed as the major isoform responsible for metabolizing CBZ 
to its active metabolite CBZ-10,11-epoxide. Since CBZ 
induces its own metabolism, the half-life is variable. The 
average half-life can range from 35 to 40 hours following 
a single dose of CBZ-ERC and 12 to 17 hours following 
repeated dosing of CBZ-ERC.
In a pharmacokinetic study conducted in patients 
with epilepsy, twice-daily CBZ-ERC was shown to be 
bioequivalent to immediate-release formulations of CBZ 
given four times daily (Garnett et al 1998). Minimizing 
the ﬂ  uctuations in serum CBZ concentrations inherent in 
immediate-release formulations was an important factor in 
the development of CBZ-ERC. Low peak-to-trough blood 
level variability ensures that blood CBZ levels remain Neuropsychiatric Disease and Treatment 2006:2(1) 6
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relatively stable (Stevens et al 1998). In studies of CBZ 
in patients with epilepsy, conversion from immediate- to 
extended-release CBZ resulted in marked reductions in 
common dose-related CNS side effects. Pharmacokinetic 
analysis showed marked variability in absorption and blood 
drug concentrations with immediate-release formulations 
of CBZ compared with CBZ-ERC. These ﬁ  ndings suggest 
that the improved CNS tolerability observed in patients 
treated with CBZ-ERC is a result of smoother drug deliv-
ery and reduced variability in absorption provided by the 
extended-release formulation (Miller et al 2004b). These 
clinical ﬁ  ndings, in addition to twice daily dosing with 
CBZ-ERC, should improve patient compliance by pro-
viding a more convenient dosing regimen and improved 
tolerance with fewer side effects.
Clinical studies
Efﬁ  cacy
For more than 30 years, CBZ has been used to treat 
bipolar disorder. Early controlled trials of CBZ in the 
treatment of acute mania were conducted with conven-
tional immediate-release formulations and confounded by 
coadministration with lithium or standard antipsychotics. 
In the ﬁ  rst double-blind, placebo-controlled study of CBZ 
in affectively ill patients (ie, bipolar, unipolar depression, 
schizoaffective illness), preliminary results showed that 
7 of the ﬁ  rst 10 patients treated with immediate-release 
CBZ responded favorably with an antimanic, an antidepres-
sant, or a prophylactic response (Ballenger et al 1978). In 
comparative studies, immediate-release CBZ was found to 
be as efﬁ  cacious as lithium in the treatment of acute mania 
in bipolar disorder (Okuma et al 1990; Small et al 1991; 
Emilien et al 1996). In one study, a 4-week, double-blind, 
multicenter trial involving 105 patients aged 13–65 years 
with manic or mixed bipolar disorder, 62% of patients in 
the immediate-release CBZ group showed moderate to 
marked amelioration of manic symptoms (as judged by 
the treating physician) at ﬁ  nal assessment, compared with 
59% in the lithium group (not signiﬁ  cant) (Okuma et al 
1990). In a separate 4-week, comparative, double-blind 
study, immediate-release CBZ monotherapy (n = 15) and 
valproate monotherapy (n = 15) were found to be compa-
rably effective in the treatment of acute mania in patients 
hospitalized with bipolar disorder (Vasudev et al 2000). 
The primary efﬁ  cacy analysis in that study revealed that 
the mean Young Mania Rating Scale (YMRS) score in the 
valproate group decreased signiﬁ  cantly more than in the 
immediate-release CBZ group, although rates of response 
( 50% decrease in total YMRS score from baseline) were 
not signiﬁ  cantly different between the two groups, as favor-
able clinical responses were attained by 53% of patients 
in the immediate-release CBZ group and 73% of patients 
in the valproate group.
While the efﬁ  cacy of CBZ in treating acute mania asso-
ciated with bipolar I disorder has been well characterized, 
evidence suggests that clinical responses to this agent are 
independent of symptomatology or bipolar subtype. In 
particular, a 21-day, open-label study involving 36 patients 
with bipolar disorder revealed that immediate-release CBZ 
reduced Hamilton Depression Rating Scale (HDRS) scores 
by an average of 72.7% (from 32.6 to 8.9; p   0.0001 for 
change relative to baseline) between baseline and end point 
in the subset of patients with bipolar depression (n = 27) 
and by an average of 50.4% (from 35.1 to 17.4; p = 0.0009 
for change relative to baseline) in the subset of patients 
with depressive mania (n = 9) (Dilsaver et al 1996). More 
recently, a retrospective chart review of patients treated in 
a private practice setting found that CBZ-ERC also appears 
to be effective in reducing the symptoms of bipolar II dis-
order (Ginsberg 2004a). Of the 111 patients treated with 
CBZ-ERC in that review (85% of whom were classiﬁ  ed 
as being “markedly ill”, “severely ill”, or “extremely ill” 
at the time of treatment initiation), 82 (74%) experienced 
a response to treatment as indicated by the achievement 
of a Clinical Global Impression-Improvement (CGI-I) 
score  3.
Aside from exhibiting efﬁ  cacy in the acute treatment of 
bipolar disorder, CBZ has also been found to be effective 
as maintenance therapy in  10 controlled or partially 
controlled studies, with a cumulative “marked or excel-
lent” response rate of approximately 61% (Denicoff et al 
1997). Several studies have compared the prophylactic 
efﬁ  cacy of immediate-release CBZ with that of lithium, 
which, in a pooled analysis of maintenance studies averag-
ing 1.5 years in length, was found to reduce the likelihood 
of manic recurrence by a factor of 2.5 and the likelihood 
of depressive recurrence by a factor of 1.8 (Goodwin 
and Jamison 1990; Baldessarini et al 1996). Comparison 
studies involving immediate-release CBZ and lithium 
have found overall response rates to be similar, with no 
trends indicating one agent’s superiority to the other in 
the maintenance setting. A meta-analysis of clinical data 
from 10 double-blind, randomized, comparative trials 
of immediate-release CBZ vs lithium as maintenance 
therapy found a relapse rate of 60% in lithium-treated 
patients vs 55% of CBZ-treated patients; the difference Neuropsychiatric Disease and Treatment 2006:2(1) 7
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between the groups was not signiﬁ  cant (Davis et al 1999). 
In one recent randomized, double-blind study comparing 
the prophylactic efficacy of immediate-release CBZ 
and lithium in bipolar disorder, lithium was superior to 
immediate-release CBZ in terms of 2.5-year hospitalization 
rates (lithium, 26%; immediate-release CBZ, 62%; 
p = 0.012) in patients with “classical” bipolar I disor-
der (without mood-incongruent features and psychiatric 
comorbidity and without mixed states; n = 67), while 
immediate-release CBZ showed a trend toward being 
more effective (2.5-year hospitalization rates: lithium, 
44%; immediate-release CBZ, 31%; p = 0.34) in the 
more heterogeneous “nonclassical” subgroup of patients 
(n = 104).These findings suggest that patients with 
classical features beneﬁ  t more from prophylactic therapy 
with lithium, while those with nonclassical features may 
beneﬁ  t more from prophylaxis with CBZ, which appears 
to provide a broader spectrum of activity (Greil et al 1998; 
Kleindienst et al 2000).
Efﬁ  cacy of CBZ-ERC in acute mania
Recently, two large 3-week, double-blind, randomized, 
placebo-controlled, multicenter trials demonstrated that 
monotherapy with twice-daily CBZ-ERC was effective in 
the treatment of acute mania in patients with bipolar I dis-
order experiencing manic or mixed episodes (Weisler et al 
2004c, 2005). To be eligible for enrollment in these studies, 
patients had to be  18 years old and meet DSM-IV criteria 
for bipolar I disorder with current episode manic or mixed 
and with manic symptoms severe enough to necessitate 
hospitalization. A history of  1 previous manic or mixed 
episode and a minimum baseline total score of 20 on the 
YMRS were required. The initial 400-mg dose of CBZ-ERC 
or placebo could be titrated by the investigators between 
200 mg and 1600 mg in daily increments of 200 mg. 
Efﬁ  cacy assessments were carried out weekly and included 
the YMRS, the Clinical Global Impression (CGI) scale, 
and the HDRS.
To better elucidate the results from these two 
similar trials, the data were combined and the efﬁ  cacy 
and safety of CBZ-ERC were evaluated based on the 
combined study population. Pooled data from these 
two pivotal studies (which took place across a total of 
40 study sites – 34 in the United States and 6 in India) 
included a total of 443 patients, 223 of whom were 
randomized to double-blind treatment with CBZ-ERC 
and 220 of whom were randomized to receive placebo. 
A total of 240 randomized patients (54%) in the pooled 
analysis completed the 21-day study period, and the rate 
of discontinuation due to lack of efﬁ  cacy was found to be 
higher in the placebo group (22%) than in the CBZ-ERC 
group (10%).
The primary efﬁ  cacy endpoint was the YMRS total score 
at the end of the double-blind treatment period. As shown in 
Figure 1, using the last observation carried forward analysis, 
CBZ-ERC-treated patients in the combined patient popula-
tion had signiﬁ  cantly greater decreases in mean YMRS scores 
from baseline than those in the placebo group at day 7, 14, 
and day 21, the primary endpoint (p   0.0001 at all time 
points). By the end of the trial, 52% of CBZ-ERC-treated 
patients in the combined population had responded ( 50% 
reduction in YMRS score) vs 26% of placebo-treated patients 
(p   0.0001). Patients receiving CBZ-ERC also experienced 
signiﬁ  cantly greater improvements in symptoms ratings on 
both CGI-Improvement (CGI-I) and CGI-Severity (CGI-S) 
scales than those treated with placebo (p   0.0001) (Weisler 
et al 2004a).
Subgroup analyses of the pooled data from these two 
pivotal studies showed that CBZ-ERC reduced both manic 
and depressive symptoms. At endpoint, there were signiﬁ  -
cant reductions in mean YMRS total scores in both manic 
(p   0.0001) and mixed (p   0.01) bipolar patients treated 
with CBZ-ERC. Importantly, CBZ-ERC treatment led to sig-
niﬁ  cant improvement in the severity of depressive symptoms 
in mixed bipolar I patients (p   0.05) and in the combined 
patient population (p = 0.01) as evidenced by signiﬁ  cant 
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decreases in HDRS total scores. The reduction in depressive 
symptoms experienced by patients treated with CBZ-ERC 
therapy in this trial suggests that CBZ may have true bimodal 
effects in bipolar disorder (Weisler et al 2004a).
As little is known about the efﬁ  cacy of CBZ-ERC in 
long-term treatment, a 6-month open-label extension study 
was conducted among patients who had completed one of 
two previous 3-week, double-blind, placebo-controlled 
evaluations of CBZ-ERC for acute mania (Ketter et al 
2004). Ninety-two patients were enrolled in the study; 67% 
were mixed and 33% manic. Of the 77 patients treated with 
CBZ-ERC and evaluated in the intent-to-treat population, 
14.3% relapsed during the 6-month study (7 had received 
prior treatment with CBZ-ERC and 4 with placebo). The 
observed mean time to relapse was approximately 2 months. 
Interestingly, a relapse rate of 14% compares favorably 
with a previously reported relapse rate of 29% for lithium 
therapy in a meta-analysis of 19 double-blind, randomized 
controlled trials of lithium prophylaxis in 865 patients 
(Davis et al 1999). During this open-label treatment with 
CBZ-ERC, patients who had previously been treated with 
placebo had signiﬁ  cant improvements in YMRS and HDRS 
in the ﬁ  rst month of active therapy, which were maintained 
over the 6-month period (Figures 2 and 3). In addition, 
patients who had received prior CBZ-ERC therapy showed 
a trend toward continued improvement in YMRS scores 
(Ketter et al 2004).
Tolerability and patient 
acceptability
The pooled analysis of safety data from the two 3-week 
trials indicated that CBZ-ERC was generally well tolerated 
in both manic and mixed bipolar patients. The most fre-
quently reported treatment-emergent adverse events among 
CBZ-ERC-treated patients (with an incidence  5% and at 
least twice the rate of placebo patients) included dizziness, 
somnolence, nausea, vomiting, ataxia, and pruritis (Weisler 
et al 2004b). The most common adverse events observed 
with long-term CBZ-ERC therapy were typical of CBZ and 
included headache, dizziness, and mild rash (Ketter et al 
2004).
Aplastic anemia and agranulocytosis have been 
observed rarely with CBZ, and no incidences were reported 
with CBZ-ERC treatment in both the acute and long-term 
studies. There was no clinically signiﬁ  cant change in 
mean weight gain ( 7% increase from baseline) among 
the pooled study population in 3-week studies or in the 
6-month trial, although a small percentage (5%) of patients 
did experience clinically signiﬁ  cant weight gain during 
the trials (Ketter et al 2004; Weisler et al 2004, 2005). No 
statistically signiﬁ  cant alterations in electrocardiogram 
variables (QTc) and no meaningful change in non-fasting 
blood glucose were reported with long-term CBZ-ERC 
therapy (Ketter et al 2004).
Total plasma cholesterol (TC) concentrations have been 
shown to increase with CBZ-ERC treatment. In one of the 
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3-week studies, TC, low-density lipoprotein cholesterol 
(p   0.0001), and high-density lipoprotein-cholesterol 
(HDL-C) increased signiﬁ  cantly (p   0.01) from base-
line measurements in patients treated with CBZ-ERC 
(Weisler et al 2005). Despite these increases in cholesterol, 
TC to HDL-C ratio was 4 to 1 at baseline and endpoint, 
which is not thought to be problematic for cardiovascular 
disease. Importantly, results from a 6-month CBZ-ERC 
extension study showed no further increase in plasma 
cholesterol concentrations in patients who were previ-
ously on CBZ-ERC in the 3-week studies (Ketter et al 
2004). This finding suggests that the increase in TC 
concentrations is not continuous, although no deﬁ  nitive 
conclusion on the effects of CBZ-ERC on cholesterol 
concentrations can be made without fasting cholesterol 
measurements.
Studies have shown that patients with epilepsy tran-
sitioned from immediate-release CBZ formulations to 
CBZ-ERC have reported fewer and less severe adverse 
events and greater patient satisfaction (Ficker 2004; 
Miller et al 2004a). In one 3-month, open-label study, 
patients with epilepsy who switched from their current 
immediate-release CBZ product to an equal total daily dose 
of CBZ-ERC experienced both a decreased occurrence and 
a decreased severity of adverse events, demonstrating the 
beneﬁ  ts of CBZ-ERC in terms of safety and tolerability 
(Ficker 2004). To further deﬁ  ne the improved tolerability 
of CBZ-ERC, a 3-month, multicenter, open-label study 
employed the Adverse Event Proﬁ  le (AEP) questionnaire 
to measure the adverse event changes associated with 
switching adult patients with epilepsy from immediate-
release CBZ to equal daily doses of CBZ-ERC. Analysis 
of the AEP total scores at end point showed that patients 
converted to CBZ-ERC exhibited statistically signiﬁ  cant 
mean decreases in all common CNS side effects (sedation, 
vertigo, ataxia, difﬁ  culty in coordination, confusion, and 
diplopia) as a result of transitioning from immediate-
release CBZ to CBZ-ERC (p   0.0001 for all side effects). 
In addition, there was a 46% decrease from baseline in the 
number of patients with “toxic” AEP scores ( 45) (Miller 
et al 2004a). Overall, it appears that CBZ-ERC may be 
more tolerable than immediate-release CBZ, as transition 
to CBZ-ERC therapy signiﬁ  cantly reduces the frequency 
and severity of drug-induced side effects.
Future needs
While randomized clinical trials have deﬁ  nitively con-
ﬁ  rmed the efﬁ  cacy of CBZ-ERC in the treatment of manic 
symptoms in patients with manic or mixed bipolar disorder, 
the full spectrum of beneﬁ  t provided by CBZ-ERC awaits 
comprehensive characterization in future studies. For 
example, CBZ-ERC has been linked to improvements 
in safety, tolerability, and patient satisfaction relative to 
what is seen in association with immediate-release CBZ 
in patients with epilepsy, and it has been hypothesized 
that CBZ-ERC provides similar beneﬁ  ts in patients with 
bipolar disorder. Nonetheless, because epilepsy and bipolar 
disorder are separate entities with distinct pathophysi-
ological mechanisms, the potential merits of CBZ-ERC 
in comparison with immediate-release CBZ remain to be 
examined in a population speciﬁ  cally consisting of patients 
with bipolar disorder.
Aside from the relative beneﬁ  ts of extended-release 
delivery of carbamazepine, another area that warrants 
further study is the efﬁ  cacy of CBZ-ERC in the prophylaxis 
of bipolar disorder. Results from a recent 6-month, open-
label study were promising, with only 14% of patients 
experiencing recurrences during maintenance therapy with 
CBZ-ERC. However, because of the open-label nature of 
that study, and since the study involved only a relatively 
small number of patients, all of whom had completed a 
full course of treatment (CBZ-ERC or placebo) in one of 
two previous randomized trials, the generalised ﬁ  ndings 
that were made remain to be assessed in a double-blind 
trial involving a more inclusive study population. Another 
notable ﬁ  nding made in these recent clinical trials is 
that of significantly reduced depressive symptoms in 
patients receiving CBZ-ERC for bipolar disorder, and 
studies designed speciﬁ  cally to evaluate the antidepres-
sant effects of CBZ-ERC may therefore also be valuable 
in providing a clearer picture of the beneﬁ  ts associated 
with this agent.
Conclusion
The clinical trials discussed in this review are the only 
known double-blind, placebo-controlled studies of 
CBZ-ERC in the treatment of acute mania in bipolar I 
disorder. In these trials, CBZ-ERC demonstrated response 
rates comparable to those of lithium, valproate, and atypical 
antipsychotics reported in other double-blind, placebo-
controlled studies in acute bipolar mania (McElroy et al 
2000). In the pooled analysis of clinical data from the two 
3-week studies, signiﬁ  cant improvement in manic symp-
toms was noted within 1 week of initiation of CBZ-ERC 
therapy (the ﬁ  rst measurement taken), with continued 
reduction in manic symptoms over the treatment period Neuropsychiatric Disease and Treatment 2006:2(1) 10
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(Weisler et al 2004a). Additionally, the extended-release 
formulation allowed a more rapid dosage titration (starting 
at 200 mg bid on day 1 and increasing by up to 200 mg 
per day), permitting faster responses for some patients 
relative to what is usually achievable with immediate-
release CBZ. A subgroup analysis of the same combined 
patient population revealed that CBZ-ERC improved both 
manic and depressive symptoms in patients experiencing 
a mixed episode (Weisler et al 2004, 2005). Importantly, 
CBZ-ERC-treated patients with mixed episodes who 
participated in the 6-month extension study maintained a 
signiﬁ  cant decrease in HDRS score from the baseline of the 
double-blind studies to day 1 (p   0.0001) of the extension 
study and end point (month 6) (p = 0.0003). Overall, there 
was no evidence of worsening of depressive symptoms 
among patients receiving up to 6 months of CBZ-ERC 
therapy (Ketter et al 2004).
Patients with mixed episodes have been shown to have 
a poor response to lithium monotherapy and often require 
multiple agents for successful treatment of the manic and 
depressive components of the mixed state (Montgomery 
et al 2000). The signiﬁ  cant reduction in both manic and 
depressive symptoms demonstrated in patients with mixed 
episodes during CBZ-ERC therapy suggests further inves-
tigation into CBZ-ERC as a treatment for bipolar depres-
sion. Moreover, as the extent of improvement in depressive 
symptoms may not have been captured in the relatively brief 
3-week studies and 6-month extension study, additional 
controlled trials of longer duration would be warranted to 
assess the efﬁ  cacy of CBZ-ERC in patients with bipolar 
depression, including those with bipolar I or bipolar II 
disorder.
Safety and tolerability are major factors in the selection of 
a therapeutic agent for bipolar patients. In the 3-week studies 
discussed in this review, the rapid dose-titration schedule 
of CBZ-ERC was aggressive at 200 mg/day and may have 
played a role in patient tolerability to CBZ during the ﬁ  rst 
week of the study (Weisler et al 2004c, 2005). In outpatient 
settings, titration may be slower, which may minimize the 
occurrence of common CNS and GI side effects.
Two very rare but serious adverse events linked to 
CBZ treatment are aplastic anemia and agranulocytosis, 
for which CBZ carries box warnings. However, some cli-
nicians may have misconceptions about the frequency of 
aplastic anemia and agranulocytosis in patients treated with 
CBZ. The overall risk of developing these reactions is very 
low – about 5–8 times the natural occurrence (6 per million 
patient years for aplastic anemia and 2 per million patient 
years for agranulocytosis) (Shire 2005; Pellock 1987). No 
occurrences of aplastic anemia or agranulocytosis were 
reported with CBZ-ERC in either the short-term or long-
term studies, although none would be expected since the 
patient populations were inadequately large to encounter 
such a reaction.
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